Legal status · Australia
Is CT-868 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. CT-868 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile.
CT-868 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| Note | No filing; programme discontinued. |
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 1 of 2 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the CT-868 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
CT-868 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What CT-868 is
Its phase 2 in 103 adults with type 2 diabetes cut glycated haemoglobin 1.61 to 2.24 percentage points against placebo but produced only 2.9 percent weight loss. Roche discontinued it in July 2026 in favour of another compound from the same acquisition.
1 billion dollars. It later received the nonproprietary name acmopatide.
Mechanism: A dual agonist at the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, described by its developers as fully biased toward cyclic AMP signalling. Signalling bias means the ligand preferentially activates the G protein and cyclic AMP arm of receptor signalling while producing little beta-arrestin recruitment, which reduces receptor internalisation and desensitisation.
Regulatory history: Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for CT-868 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
CT-868 in other countries
Frequently asked questions
Is CT-868 legal in Australia?
No. CT-868 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile. Note: No filing; programme discontinued.
Can I buy CT-868 in Australia?
No approved product exists to buy. In Australia CT-868 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: No filing; programme discontinued.
Is CT-868 TGA approved?
No. In Australia CT-868 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes.. On the evidence, 1 human study is cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for CT-868 live on its compound profile.
CT-868 profileThis page is general information about the regulatory status of CT-868 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.